SynthesisInternational journal of molecular sciences2018
The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review.
Synthesis in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
63 citing papers in PubMed, 2 syntheses or guidelines pooled it, 159 citations in OpenAlex.
- Gray Matter Alterations in Panic Disorder: A Voxel-Wise Meta-Analysis.Psychiatry and clinical psychopharmacology · 2023Pooled it
- The efficacy and safety of buprenorphine for the treatment of depression: A systematic review and meta-analysis.Journal of psychiatric research · 2023Pooled it
- Trial
- Suicidal ideation in adults with opioid use disorder treated with buprenorphine-naloxone versus extended-release naltrexone.The American journal of drug and alcohol abuse · 2025Trial
- Longitudinal study of impact of medication for opioid use disorder on Hamilton Depression Rating Scale.Journal of affective disorders · 2022Trial
- Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.Addiction (Abingdon, England) · 2022Trial
- Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Extended-release injection vs sublingual buprenorphine for illicit opioid use in pregnant patients with depression and/or anxiety.Drug and alcohol dependence · 2026Article
- Pharmacological and Non-Pharmacological Interventions for Non-Suicidal Self-Injury: A Narrative Review.Alpha psychiatry · 2026Review
- Implementation facilitation improves readiness for emergency department-initiated buprenorphine to treat opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Antidepressants and the endogenous opioid system.Biochemical pharmacology · 2025Review
- Correlates of mental defeat in individuals with chronic non-cancer pain on long-term opioid therapy.Pain medicine (Malden, Mass.) · 2025Article
- Comparing quality of life methadone and buprenorphine for opioid substitution treatment in Iran.Scientific reports · 2025Article
- Opiophobia: Misinformation, Misconceptions, Misrepresentations, Perspectives, and Consequences.ACS pharmacology & translational science · 2025Review
- Telemedicine-delivered treatment for substance use disorder: A scoping review.Journal of telemedicine and telecare · 2025Article
- Can dextromethorphan-bupropion reduce mental pain in depressed individuals? A generating hypothesis overview perspective.Annals of general psychiatry · 2025Review
- Redefining Ketamine Pharmacology for Antidepressant Action: Synergistic NMDA and Opioid Receptor Interactions?The American journal of psychiatry · 2025Review
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Interictal Dysphoric Disorder in Epilepsy and Its Relationship with Specific Clinical and Demographic Variables.Psychiatry and clinical psychopharmacology · 2024Article
- Prescription opioid dispensing patterns among patients with schizophrenia or bipolar disorder.BMC psychiatry · 2024Observational
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although several pharmacological options to treat depression are currently available, approximately one third of patients who receive antidepressant medications do not respond adequately or achieve a complete remission. Thus, novel strategies are needed to successfully address those who did not respond, or partially respond, to available antidepressant pharmacotherapy. Research findings revealed that the opioid system is significantly involved in the regulation of mood and incentives salience and may be an appropriate target for novel therapeutic agents. The present study aimed to systematically review the current literature about the use of buprenorphine (BUP) for major depression, treatment-resistant depression (TRD), non-suicidal self-injury (NSSI) behavior, and suicidal behavior. We investigated Pubmed and Scopus databases using the following keywords: "buprenorphine AND depression", "buprenorphine AND treatment resistant depression", "buprenorphine AND suicid*", "buprenorphine AND refractory depression". Several evidence demonstrate that, at low doses, BUP is an efficacious, well-tolerated, and safe option in reducing depressive symptoms, serious suicidal ideation, and NSSI, even in patients with TRD. However, more studies are needed to evaluate the long-term effects, and relative efficacy of specific combinations (e.g., BUP + samidorphan (BUP/SAM), BUP + naloxone (BUP/NAL), BUP + naltrexone) over BUP monotherapy or adjunctive BUP treatment with standard antidepressants, as well as to obtain more uniform guidance about the optimal BUP dosing interval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.